HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 2007-0803v1 26/3/675    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Google Scholar Articles by Reese, J. S. Articles by Gerson, S. L. PubMed PubMed Citation Articles by Reese, J. S. Articles by Gerson, S. L.

TISSUE-SPECIFIC STEM CELLS

Bone Marrow-Derived Cells Exhibiting Lung Epithelial Cell Characteristics Are Enriched In Vivo Using Methylguanine DNA Methyltransferase-Mediated Drug Resistance

^aCenter for Stem Cell and Regenerative Medicine, Case Comprehensive Cancer Center, Ireland Cancer Center at University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
^bDivision of Human Gene Therapy, University of Alabama Birmingham, Birmingham, Alabama, USA

Key Words. Methylguanine DNA methyltransferase • Bone marrow-derived stem cell • Enrichment • Gene transfer

Correspondence: Stanton L. Gerson, M.D., Case Comprehensive Cancer Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, Ohio 44106, USA. Telephone: 216-844-8565; Fax: 216-844-4975; e-mail: Stanton.gerson{at}case.edu

Received September 21, 2007; accepted for publication December 14, 2007.
First published online in STEM CELLS EXPRESS   January 10, 2008.



Previous studies have suggested that donor bone marrow-derived cells can differentiate into lung epithelial cells at low frequency. We investigated whether we could enrich the number of donor-derived hematopoietic cells that have type II pneumocyte characteristics by overexpression of the drug resistance gene methylguanine DNA methyltransferase (MGMT). MGMT encodes O⁶-alkylguanine DNA alkyltransferase (AGT), a drug resistance protein for DNA damage induced by N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU), and the mutant P140K MGMT confers resistance to BCNU and the AGT inactivator O⁶-benzylguanine (BG). For this study, we used two MGMT selection models: one in which donor cells had a strong selection advantage because the recipient lung lacked MGMT expression, and another in which drug resistance was conferred by gene transfer of P140K MGMT. In both models, we saw an increase in the total number of donor-derived cells in the lung after BCNU treatment. Analysis of single-cell suspensions from 28 mice showed donor-derived cells with characteristics of type II pneumocytes, determined by surfactant protein C (SP-C) expression. Furthermore, an increase in the percentage of donor-derived SP-C cells was noted after BCNU or BG and BCNU treatment. This study demonstrates that bone marrow cells expressing MGMT can engraft in the lung and convert into cells expressing the type II pneumocyte protein SP-C. Furthermore, these cells can be enriched in response to alkylating agent-mediated lung injury. These results suggest that expression of MGMT could enhance the capacity of bone marrow-derived cells to repopulate lung epithelium, and when used in combination with a gene of interest, MGMT could have therapeutic applications.